Innoscience’s First Annual Report After Listing: Revenue of RMB 830 Million, Adjusted Net Loss of RMB 835 Million

Leidi Network, Lei Jianping, April 10 Innoscience (02577.HK) recently released its financial results for the fiscal year ended December 31, 2024. The report shows that Innoscience’s revenue for 2021, 2022, 2023, and 2024 was RMB 68.22 million, RMB 136 million, RMB 593 million, and RMB 828 million, respectively; gross losses were RMB 182 million, RMB 394 million, RMB 362 million, and RMB 161 million, respectively. Innoscience’s 2024 revenue increased by 39.8% year-on-year; overseas revenue amounted to RMB 126 million, up 118.1% year-on-year, representing 15.3% of total revenue. Operating losses for 2021, 2022, 2023, and 2024 were RMB 1 billion, RMB 1.176 billion, RMB 983 million, and RMB 960 million, respectively; total comprehensive losses for the year were RMB 3.4 billion, RMB 2.2 billion, RMB 1.1 billion, and RMB 1.047 billion, respectively. Innoscience’s adjusted net loss for 2024 was RMB 835 million, compared to an adjusted net loss of RMB 1.016 billion in the prior-year period. Total liabilities stood at RMB 10.7 billion, RMB 2.735 billion, RMB 2.627 billion, and RMB 2.576 billion in 2021, 2022, 2023, and 2024, respectively. Innoscience’s executive directors are Dr. Weiwei Luo (Chairman), Hyung Ja Son, Dr. Jingang Wu (CEO), and Shan Zhong (CFO); non-executive directors are Dr. Can Wang, Ms. Yanhong Zhang, and Ms. Mizi Cui; independent non-executive directors are Xianrong Huang, Dr. Jiming Yi, Dr. Shining Yang, and Dr. Zhenghao Chen.

CA Markets: Innoscience’s Revenue Up 51%; Hong Kong Market Revalues Company at Cash Flow Inflection Point

A power semiconductor company still operating at a loss finds it easiest to tell a story through shipment volume—and hardest to substantiate that story with cash flow. In the first half of 2026, Innoscience shipped 547 million units, with revenue up 50.6% year-on-year and gross margin rising to 11.6%. Operating cash flow turned from a net outflow of RMB 387 million in the prior-year period to a net inflow of RMB 169 million. For Hong Kong-listed stock 02577, the most valuable change in this interim report is not how fast any particular application segment grew—but rather that scale, gross margin, and cash flow all moved clearly in the same positive direction for the first time. This is still not a financial report suitable for valuation using earnings multiples. The company reported a loss of RMB 309 million for the period; R&D expenses of RMB 185 million exceeded gross profit of RMB 97 million, while capital expenditures rose to RMB 398 million. Innoscience’s stock—and potentially broader Hong Kong-listed technology and semiconductor thematic products covering third-generation semiconductors—must simultaneously address four critical questions: (1) Is revenue coming from higher-value markets? (2) Can gross margin improvement be sustained? (3) Can positive operating cash flow be repeated? And (4) Can borrowing and inventory buildup associated with capacity expansion translate into returns? First checkpoint: Where did the RMB 834 million in revenue come from? Revenue for the first half of the year totaled RMB 833.6 million, up from RMB 553.4 million in the prior-year period. By product category: GaN discrete devices and integrated circuits generated RMB 230.5 million, up 11.1%; wafer sales reached RMB 187.5 million, up 73.5%; and module sales amounted to RMB 411.8 million, up 74.4%. Growth was driven primarily by wafers and modules—not uniformly across all product lines—making shifts in product mix more significant than overall revenue growth. The high module growth rate signals the company’s expansion from single-component devices toward more complete power solutions, which—in theory—increases the value per customer project. Wafer revenue growth reflects broadening external ecosystem support and expanding customer orders. Yet these two businesses carry distinct risks: modules entail greater responsibility for packaging, system integration, and customer delivery; wafer revenue is more sensitive to capacity utilization, yield rates, and customers’ in-house R&D timelines. The market should not treat a 74% growth rate as costless scale expansion. High-value applications are reshaping the revenue structure. The company disclosed that revenue from premium applications—including AI data centers, industrial energy storage, and new-energy vehicles—reached RMB 532.3 million, up 70% year-on-year, outpacing consumer electronics revenue of RMB 301.4 million, which grew 26%. AI and data-center chip shipments surged 183%, automotive-grade chips rose 103%, and shipments for humanoid robotics totaled 464,600 units—a 50% increase. These figures indicate that incremental growth is shifting away from mature segments like fast chargers toward higher-power, longer-certification-cycle markets. It is essential to distinguish between shipment growth and actual revenue contribution. AI, automotive, and robotics projects typically undergo lengthy cycles—from sampling and qualification to mass production—so shipment volumes often precede revenue and margin expansion. During the first half, the company added 747 key-market customer introductions, signaling a widening future pipeline—but this does not guarantee that all 747 will convert into mass-production orders. Valuation should reflect only those projects that have passed qualification and achieved stable delivery—not assign full terminal value to every introduced project. Consumer electronics remain the foundation. RMB 301.4 million in revenue and 26% growth provide manufacturing scale, broad customer coverage, and cash flow—while also helping to absorb fixed costs.

Innospec (IOSP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

5 days ago

Innospec Inc forecasts earnings growth for the September 2026 quarter, releasing results November 3. Analysts expect 13.4% year-over-year EPS growth, though a Hold rating indicates uncertainty on beating estimates.

Yahoo Finance UK

2026-05-25

Will Bigger Capital Returns Amid Softer Earnings Metrics Change Innospec's (IOSP) Narrative?

2026-06-23

Innospec Inc (IOSP) Valuation: PE, PB & Fair Value Analysis

2026-06-25

Innospec Inc. (IOSP) Stock Forecast and Price Target Prediction for 2027

2026-07-02

Did Innospec’s (IOSP) Broad Russell Index Exit Just Recast Its Passive Demand and Risk Profile?

2026-07-30

Innospec Inc (IOSP) Risk Assessment: Volatility, Financial Risk & Investment Risk